对于精神分裂症患者,HMG-CoA减少酶抑制剂 (他类药物) 与安慰剂相比
Yusuke Saishoji1,2, Saehyeon Kim3, Masahiro Banno2,4
1Department of General Medicine, Hakujyuji Hospital, Fukuoka, Japan.
The Cochrane database of systematic reviews
|September 19, 2025
概括
这次审查将评估他类药物 (HMG-CoA减少酶抑制剂) 与安慰剂的益处和危害,用于治疗成人精神分裂症. 我们的目标是提供关于他类药物的有效性和安全性的证据.
科学领域:
- 精神病学和心理健康 精神病学和心理健康
- 药理学和治疗学 药理学和治疗学
- 临床研究方法论 临床研究方法论
背景情况:
- 精神分裂症是一种复杂的精神疾病,具有显著的未满足的治疗需求.
- 目前的抗精神病治疗有局限性和副作用.
- HMG-CoA减少酶抑制剂 (他类药物) 广泛用于心血管疾病,具有免疫调节和神经保护性质,可能与精神分裂症有关.
研究的目的:
- 系统地评估他类药物的疗效和安全性,作为治疗成年精神分裂症的干预措施.
- 在被诊断为精神分裂症的个体中,比较他类药物的效果与安慰剂.
主要方法:
- 这是柯克伦审查的协议,遵循严格的系统审查方法.
- 审查将包括随机对照试验,比较成年精神分裂症患者的他类药物与安慰剂.
- 将提取临床结果,不良事件和其他相关措施的数据.
主要成果:
- 本章节将介绍包括在内研究的综合发现,一旦审查完成.
- 结果将详细说明使用他类药物的益处 (例如,症状改善) 和危害 (例如,副作用).
结论:
- 结论将基于关于他类药物在精神分裂症管理中的作用的综合证据得出结论.
- 这些发现将为临床实践和精神病药物治疗的未来研究方向提供信息.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Psychosis and Antipsychotic Drugs: Overview
817
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
817
Drug Therapy
245
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
245
Psychosis: Goals of Pharmacotherapy
476
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
476
Antidepressant Drugs: MAOIs and Other Agents
828
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
828


